Worldwide standards for clinical proteome analyses
The dream of individual medicine gets the scientific basis
This task has been significantly eased by the successful application of diagnostic polypeptide patterns in several clinical studies recently. This technological advance already enables the early detection of several diseases, for example bladder cancer, prostate cancer and chronic renal diseases, including diabetic nephropathy. The studies were published recently in Nature Medicine, Blood, Lancet Oncology and the Journal of the American Society of Nephrology.
The use of proteome analysis for the early detection differential diagnosis of several diseases is marketed via DiaPat GmbH, a subsidiary of Mosaiques Diagnostics & Therapeutics AG. According to the company, clinical proteome analysis is also of high value in the development of pharmaceuticals and will result in faster and safer development. Effects and side-effects of drugs can be evaluated on a multidimensional molecular level with unsurpassed precision using diagnostic polypeptide patterns. Diagnostic patterns (DiaPat) are patterns of thousand proteins and peptides, which reflects the difference between healthy and disease, based on indicative changes of specific proteins and peptides. The extremely complex and expensive drug development process can be significantly improved by the DiaPat method, by reducing the rates and the time for drug development.
Other news from the department research and development
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.